Evidence map›Paper›PMID 32252500›Full record

ArticleTurkish journal of medical sciences2020

A study of Drynaria fortunei in modulation of BMP–2 signalling by bone tissue engineering

Guo-Chung Dong, Tzn-Yuan Ma, Chi-Han Li, Chih-Ying Chi, Chao-Ming Su, Chih-Ling Huang, Yan-Hsiung Wang, Tzer-Ming Lee

Open access · bronzeAbstract read
In one paragraph

Article in Turkish journal of medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Guo-Chung DongInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County, TaiwanORCID 0000-0003-1159-1718
Tzn-Yuan MaInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County, TaiwanORCID 0000-0003-3973-6544
Chi-Han LiInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County, TaiwanORCID 0000-0002-3343-6332
Chih-Ying ChiInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County, TaiwanORCID 0000-0001-5816-0224
Chao-Ming SuInstitute of Biomedical Engineering and Nanomedicine, National Health Research Institutes, Miaoli County, TaiwanORCID 000-0002-3463-287X
Chih-Ling HuangCenter for Fundamental Science, Kaohsiung Medical University Kaohsiung, TaiwanORCID 0000-0002-7323-4954
Yan-Hsiung WangSchool of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanORCID 0000-0001-8161-7472
Tzer-Ming LeeSchool of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung, TaiwanORCID 0000-0002-1873-9685
National Health Research Institutes · TWKaohsiung Medical University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background/aim: Drynaria fortunei (Gusuibu; GSB) is a popular traditional Chinese medicine used for bone repair. An increasing number of studies have reported that GSB induces osteogenic differentiation in bone marrow mesenchymal stem cells (BMSCs). These results provide insight into the application of GSB for bone tissue engineering techniques used to repair large bone defects. However, few studies have described the molecular mechanisms of GSB. Materials and methods: In the present study, the effects of GSB and naringin, a marker compound, on the binding of BMP-2 to BMPR and BMP-2-derived signal transduction were investigated using surface plasmon resonance (SPR) and coculturing with BMPR- expressed cell line, C2C12, respectively. Furthermore, naringin was also used to prepare naringin contained scaffolds for bone tissue engineering. The physical and chemical properties of these scaffolds were analysed using scanning electron microscopy (SEM) and highperformance liquid chromatography (HPLC). These scaffolds were cocultured with rabbit BMSCs in vitro and implanted into rabbit calvarial defects for bone repair assessment. Results: The results showed that GSB and naringin affect the binding of BMP and BMPR in SPR experiments. GSB is a subtle BMP modulator that simultaneously inhibits the binding of BMP-2 to BMPR-1A and enhances its binding to BMPR-1B. In contrast, naringin inhibited BMP-2 binding to BMPR-1A. In vitro studies involving the phosphorylation of signals downstream of BMPR and Smad showed that GSB and naringin affected stem cell differentiation by inhibiting BMPR-1A signalling. When using GSB for bone tissue engineering, naringin exhibited a higher capacity for slow and gradual release from the scaffold, which promotes bone formation via osteoinduction. Moreover, control and naringin scaffolds were implanted into rabbit calvarial defects for 4 weeks, and naringin enhanced bone regeneration in vivo significantly. Conclusions: GSB and its marker compound (naringin) could inhibit the binding of BMP-2 and BMPR-1A to control cell differentiation by blocked BMPR-1A signalling and enhanced BMPR-1B signalling. GSB and naringin could be good natural BMP regulators for bone tissue engineering.

Indexed as

AnimalsBone and BonesBone Morphogenetic Protein 2Bone Morphogenetic Protein Receptors, Type ICells, CulturedDrugs, Chinese HerbalFlavanonesMaleOsteogenesisPolypodiaceaeRabbitsSignal TransductionTissue EngineeringBone Morphogenetic Protein 2Bone Morphogenetic Protein Receptors, Type IDrugs, Chinese HerbalFlavanonesnaringeninBMPR-1Abone tissue engineeringnaringin

Identifiers

PMID32252500
PMCPMC7491309
OpenAlexW3014467664

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.